Plain-English translation of NCT07389876 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This trial is testing whether —a chemotherapy drug—works better when combined with other medications for treating advanced stomach cancer. Researchers want to see if adding certain helper drugs to this medication can improve outcomes for patients whose cancer has progressed after their first course of treatment.
Many people with advanced stomach cancer don't respond well enough to standard first-line treatments, and they need new options. This study explores whether combining the medication with other therapies—such as drugs that boost the immune system or cut off blood supply to tumors—might work better than the medication alone.
You likely qualify if…
You likely don't qualify if…
If you join this study, you will be assigned to one of five groups, each testing a different medication combination. Most groups involve receiving injections of the main medication twice every three weeks, sometimes combined with daily pills or additional injections. Treatment continues until your cancer stops responding or side effects become too difficult. You will have regular blood tests and imaging scans to monitor how well the treatment is working and how you are tolerating it.
AI-generated summary from trial data · Aug 5, 2026 · Not medical advice
China
Sponsor
Fudan University
Enrollment target
~250 participants
Started
September 2025
Primary completion
September 2027
Age range
18 Years – 80 Years
Last updated on clinicaltrials.gov in February 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Wanjing Feng
Fudan University
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.